Characterization of the Photodegradation of a Human IgG1 Monoclonal Antibody Formulated as a High-Concentration Liquid Dosage Form

被引:98
|
作者
Qi, Pei [1 ]
Volkin, David B. [1 ]
Zhao, Hui [1 ]
Nedved, Michael L. [1 ]
Hughes, Robert [1 ]
Bass, Ryan [1 ]
Yi, Sun C. [1 ]
Panek, Mark E. [1 ]
Wang, Dana [1 ]
Dalmonte, Paul [1 ]
Bond, Michael D. [1 ]
机构
[1] Centocor R&D Inc, Pharmaceut Dev Dept, Radnor, PA 19087 USA
关键词
monoclonal antibody; IgG; photostability; photodegradation; discoloration; liquid formulation; ABSORBING AMINO-ACIDS; SIMPLE DERIVATIVES; TRYPTOPHAN; STABILITY; OXIDATION; PHOTOCHEMISTRY; PHOTOPHYSICS; AGGREGATION; PROTEINS; RESIDUES;
D O I
10.1002/jps.21617
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The photodegradation of a human IgG1 monoclonal antibody has been examined in a high concentration (100 mg/mL) liquid formulation. It was observed that a yellowish color is generated when the formulation is exposed to intense and prolonged light exposure, and this discoloration occurs along with a loss in bioactivity. Extensive analytical characterization was performed to determine light induced degradation pathways that occur during exposure to intense light of ICH photodegradation conditions. It has been shown that the monoclonal antibody undergoes a combination of physical and chemical reactions under these conditions, including covalent aggregate formation, fragmentation at the hinge region, oxidation of Trp, His, and Met residues, and deamidation of Asn residues. Oxidation of Trp 94 and deamidation of Asn 93, located in the light chain CDR region, correlates with loss of bioactivity under these conditions. A series of formulation experiments were performed to elucidate the impact of the extent of light exposure, oxygen, protein concentration, and solution pH on the photostability of the formulation. Results demonstrated that photodegradation of the IgG, after intensive light exposure, can be prevented by proper secondary packaging. In addition, it is also shown that a high concentration, liquid dosage form of a human monoclonal antibody is stable upon exposure to the ambient light conditions encountered during routine manufacturing, long-term storage, and administration with proper design of formulation conditions, the primary container as well as the secondary package. (c) 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:3117-3130, 2009
引用
收藏
页码:3117 / 3130
页数:14
相关论文
共 50 条
  • [31] Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1
    Hu, Yue
    Arora, Jayant
    Joshi, Sangeeta B.
    Esfandiary, Reza
    Middaugh, C. Russell
    Weis, David D.
    Volkin, David B.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (01) : 340 - 352
  • [32] Characterization of a fully human IgG1 reconstructed from an anti-acetylcholine receptor antibody fragment
    Stassen, MHW
    Machiels, BM
    Fostieri, E
    Tzartos, SJ
    Berrih-Aknin, S
    Bosmans, E
    Parren, PWHI
    de Baets, MH
    NEUROMUSCULAR DISORDERS, 2002, 12 (7-8) : 734 - 734
  • [33] Characterization of the basic charge variants of a human IgG1 Effect of copper concentration in cell culture media
    Kaschak, Timothy
    Boyd, Daniel
    Lu, Franklin
    Derfus, Gayle
    Kluck, Brian
    Nogal, Bartek
    Emery, Craig
    Summers, Christie
    Zheng, Kai
    Bayer, Robert
    Amanullah, Ashraf
    Yan, Boxu
    MABS, 2011, 3 (06) : 577 - 583
  • [34] Comparison of Strategies in Development and Manufacturing of Low Viscosity, Ultra-High Concentration Formulation for IgG1 Antibody
    Deokar, Vaibhav
    Sharma, Alok
    Mody, Rustom
    Volety, Subrahmanyam M.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (12) : 3579 - 3589
  • [35] Development and biophysical characterization of a humanized FSH-blocking monoclonal antibody therapeutic formulated at an ultra-high concentration
    Rojekar, Satish
    Pallapati, Anusha R.
    Gimenez-Roig, Judit
    Korkmaz, Funda
    Sultana, Farhath
    Sant, Damini
    Haeck, Clement M.
    Macdonald, Anne
    Kim, Se-Min
    Rosen, Clifford J.
    Barak, Orly
    Meseck, Marcia
    Caminis, John
    Lizneva, Daria
    Yuen, Tony
    Zaidi, Mone
    ELIFE, 2023, 12
  • [36] HuMax-CD20, a novel fully human monoclonal IgG1 antibody in the treatment of rheumatoid arthritis.
    Ostergaard, M.
    Wiell, C.
    Sierakowski, S.
    Wallace, D.
    Kastberg, H.
    Petersen, J.
    Dawes, P. T.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S832 - S832
  • [37] High-Throughput Biophysical Analysis and Data Visualization of Conformational Stability of an IgG1 Monoclonal Antibody After Deglycosylation
    Alsenaidy, Mohammad A.
    Kim, Jae Hyun
    Majumdar, Ranajoy
    Weis, David D.
    Joshi, Sangeeta B.
    Tolbert, Thomas J.
    Middaugh, C. Russell
    Volkin, David B.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (11) : 3942 - 3956
  • [38] Identification and characterization of a -1 reading frameshift in the heavy chain constant region of an IgG1 recombinant monoclonal antibody produced in CHO cells
    Lian, Zhirui
    Wu, Qindong
    Wang, Tongtong
    MABS, 2016, 8 (02) : 358 - 370
  • [39] HUMAN-LYMPHOCYTE AND MONOCYTE LYSIS OF TUMOR-CELLS MEDIATED BY A MOUSE HUMAN IGG1 CHIMERIC MONOCLONAL-ANTIBODY
    SHAW, DR
    HARRISON, G
    SUN, LK
    SHEARMAN, C
    GHRAYEB, J
    MCKINNEY, S
    DADDONA, PE
    LOBUGLIO, AF
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1988, 7 (02): : 204 - 211
  • [40] Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 2
    Hu, Yue
    Toth, Ronald T.
    Joshi, Sangeeta B.
    Esfandiary, Reza
    Middaugh, C. Russell
    Volkin, David B.
    Weis, David D.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (01) : 353 - 363